Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

3SBio Given SFDA Permission for Phase III Trial of Anti-Rejection Drug

publication date: Jun 28, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio received permission from the SFDA to conduct the China arm of the multi-national Phase III trial of voclosporin, a new generation calcineurin inhibitor. 3SBio in-licensed the drug from Isotechnika Pharma of Canada in 2010. The drug suppresses immune system activity and will be tested in patients undergoing renal transplants. More details...

Stock Symbols: (NSDQ: SSRX) (TSX: ISA)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...